Dicerna Pharmaceuticals (DRNA) Receiving Somewhat Favorable Press Coverage, Study Shows
Headlines about Dicerna Pharmaceuticals (NASDAQ:DRNA) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Dicerna Pharmaceuticals earned a news sentiment score of 0.12 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 46.9730295701748 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news stories that may have impacted Accern’s analysis:
- Which Way Are Traders Betting This Stock Will Go: Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (cantoncaller.com)
- Do Analysts See Any Promise for Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA)? (cantoncaller.com)
- Global Beta Catenin Market 2018 – Boston Biomedical Inc, Dicerna Pharmaceuticals Inc, Marina Biotech Inc (blamfluie.com)
- Dicerna Pharmaceuticals, Inc. (NasdaqGS:DRNA)’s Portfolio Target Weight Hits 0.02000 After 1.26579 Profit Growth (cantoncaller.com)
- Consolidated Research: 2018 Summary Expectations for Internap, Approach Resources, Agile Therapeutics, Town … (globenewswire.com)
DRNA has been the subject of several research analyst reports. HC Wainwright reaffirmed a “hold” rating and set a $14.00 target price on shares of Dicerna Pharmaceuticals in a report on Tuesday, May 15th. ValuEngine downgraded shares of Dicerna Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, July 2nd. BidaskClub raised shares of Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, August 10th. Stifel Nicolaus lifted their target price on shares of Dicerna Pharmaceuticals from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Thursday, August 9th. Finally, Chardan Capital reaffirmed a “hold” rating and set a $14.50 target price on shares of Dicerna Pharmaceuticals in a report on Monday, August 13th. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $14.54.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.26). Dicerna Pharmaceuticals had a negative return on equity of 97.39% and a negative net margin of 1,642.81%. The business had revenue of $1.55 million during the quarter, compared to analyst estimates of $1.79 million. research analysts forecast that Dicerna Pharmaceuticals will post -1.14 EPS for the current year.
In other Dicerna Pharmaceuticals news, Director Dennis Langer sold 14,531 shares of Dicerna Pharmaceuticals stock in a transaction dated Wednesday, August 15th. The shares were sold at an average price of $16.00, for a total value of $232,496.00. Following the completion of the sale, the director now owns 29,064 shares in the company, valued at approximately $465,024. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 19.85% of the stock is owned by insiders.
About Dicerna Pharmaceuticals
Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia.
Recommended Story: Closed-End Mutual Funds (CEFs)
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.